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Purpose:Beneﬁcial mechanisms of bone marrow cell (BMC) therapy for acute ST-segment
elevation myocardial infarct (STEMI) are largely unknown in humans.Therefore, we evalu-
ated the feasibility of serial positron emission tomography (PET) and MRI studies to provide
insight into the effects of BMCs on the healing process of ischemic myocardial damage.
Methods: Nineteen patients with successful primary reteplase thrombolysis (mean 2.4h
after symptoms) for STEMI were randomized for BMC therapy (2.9×106 CD34+ cells) or
placebo after bone marrow aspiration in a double-blind, multi-center study.Three days post-
MI, coronary angioplasty, and paclitaxel eluting stent implantation preceded either BMC
or placebo therapy. Cardiac PET and MRI studies were performed 7–12days after thera-
pies and repeated after 6months, and images were analyzed at a central core laboratory.
Results:InBMC-treatedpatients,therewasadecreasein[11C]-HEDdefectsize(−4.9±4.0
vs. −1.6 ±2.2%, p =0.08) and an increase in [18F]-FDG uptake in the infarct area at risk
(0.06±0.09 vs. −0.05±0.16, p =0.07) compared to controls, as well as less left ventricu-
lar dilatation (−4.4±13.3 vs. 8.0±16.7mL/m2, p =0.12) at 6months follow-up. However,
BMC treatment was inferior to placebo in terms of changes in rest perfusion in the area
at risk (−0.09±0.17 vs. 0.10±0.17 , p =0.03) and infarct size (0.4±4.2 vs. −5.1±5.9g,
p =0.047), and no effect was observed on ejection fraction (p =0.37). Conclusion: After
the acute phase of STEMI, BMC therapy showed only minor trends of long-term beneﬁt in
patients with rapid successful thrombolysis.There was a trend of more decrease in inner-
vation defect size and enhanced glucose metabolism in the infarct-related myocardium
and also a trend of less ventricular dilatation in the BMC-treated group compared to
placebo.However, no consistentlybetteroutcomewasobservedintheBMC-treatedgroup
compared to placebo.
Keywords: stem cell therapy, myocardial infarct, PET, MRI
INTRODUCTION
Even optimal reperfusion therapy for acute ST-segment eleva-
tion myocardial infarction (STEMI) is not always effective in
preventing left ventricular (LV) remodeling, heart failure, and
compromisedclinicaloutcome(SuttonandSharpe,2000),andno
approaches are available in clinical practice to replace infarct scar
with functional myocardium (Sutton and Sharpe, 2000; Losordo
and Dimmeler, 2004; Wollert and Drexler, 2005; Rosenzweig,
2006). However, bone marrow-derived stem cell (BMC) therapy
has been demonstrated to improve the recovery of LV function
and reduce the infarct size after acute myocardial infarct (MI;
Assmus et al., 2002; Strauer et al., 2002; Britten et al., 2003;
Fernandez-Aviles et al., 2004; Wollert et al., 2004; Janssens et al.,
2006;Schachingeretal.,2006a)butrecentplacebo-controlled,ran-
domized trials have been partially controversial with regard to
functional beneﬁt after MI both in animals and humans (Janssens
et al., 2006; Lunde et al., 2006; Meyer et al., 2006; de Silva et al.,
2008; Hashemi et al., 2008; Herbots et al., 2009; Tendera et al.,
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2009). Therefore, it is not surprising that the mechanisms behind
the beneﬁcial effects are not fully elucidated (Jackson et al., 2001;
Kocher et al., 2001; Orlic et al., 2001; Balsam et al., 2004; Murry
et al., 2004; Janssens et al., 2006; Lunde et al., 2006) but paracrine
factors seem to have a major role in the process (Yeghiazarians
et al., 2009). Conﬂicting results have been explained by different
timing of bone marrow harvesting and therapy, type and num-
ber of stem cells, and different methods of cell delivery to the
myocardium at risk (Schachinger et al., 2006b).
Myocardial perfusion, metabolism, and innervation that all
determine cardiac adaptation and remodeling following MI can
bestudiedquantitativelyinvivo usingpositronemissiontomogra-
phy (PET). Moreover,serial cardiac MRI is the reference standard
for evaluating left and right ventricular function, wall motion
and infarct size. In this FINCELL-INSIGHT sub-study we applied
comprehensive cardiac imaging for evaluation of the long-term
effectsandthepotentialmechanismsof BMCtherapyontheheal-
ingprocessofischemicmyocardialdamage.Thefocuswastargeted
tochangesinperfusion,metabolism,innervation,andcardiacvol-
umetrics occurring after intracoronary infusion of BMCs early
after acute ST-elevation MI.
MATERIALS AND METHODS
PATIENTS AND STUDY DESIGN
A total of 522 consecutive patients with STEMI treated with pri-
maryintravenousthrombolytictherapyadmittedtotheUniversity
Hospitals of Turku and Oulu,Finland,between October 2004 and
February 2007 were screened for eligibility. Patients were con-
sidered eligible for the trial, if they were <75years of age, had
evidence of STEMI from an electrocardiogram (ECG), elevated
troponin levels, thrombolytic therapy given within 12h after the
onset of symptoms, no need for urgent PCI immediately after
thrombolysis, no cardiogenic shock, hemodynamic instability, or
lack of resolution of ST-segment elevations after thrombolysis,no
need for immediate coronary artery bypass graft surgery, and no
severe coexisting condition that interfered with the ability of the
patient to comply with the protocol. After exclusions, a total of
80 patients were included in the FINCELL trial (Huikuri et al.,
2008), of which 19 random patients were included to FINCELL
INSIGHT sub-study according to their willingness to participate
in additional PET and MRI studies at Turku University Hospital.
The19patientswererandomizedtoreceiveeitherBMC(n =11)or
placebo (n =8) treatment by a technician who did not participate
in any other parts of the research protocol. The study ﬂow chart
is presented in Figure 1. The clinical and angiographic character-
ization of the study population is presented in Table 1. The study
was carried out in accordance with the Declaration of Helsinki
(2000)of theWorldMedicalAssociationandwasapprovedbyThe
Ethical Committees of Turku and Northern Ostrobotnia Hospital
District. All patients gave their written,informed consent prior to
their inclusion in the study.
The time from the onset of symptoms to intravenous throm-
bolysis was 2.0h (range 0.9–4.0h) in the BMC group and 2.9h
(range1.2–7.0h)incontrols(p =0.27).Intravenousreteplasewas
used as a thrombolytic agent and the day of therapy was deﬁned
asday0.Atday3(3.2vs.3.1daysforBMCandcontrolgroup),the
pharmacological thrombolysis was followed by angioplasty and
FIGURE1|S t u d yﬂ o wc h a r t .
paclitaxel eluting stent implantation in both groups. After stent
implantation,either BMC or placebo was injected distally into the
affected artery using an “over the wire balloon,” and a short bal-
loon occlusion at the time of injection was used to prevent acute
cell loss. To conﬁrm the blinded nature of the study both for the
patients and investigators, all patients underwent bone marrow
harvestingatthemorningof angioplasty.Therandomizationcode
was opened after all imaging data were analyzed from all patients.
Baseline cardiac function was measured by cine angiography at
day 3 (same day as therapy). Cardiac MRI and PET studies were
performed 7–12days after BMC or placebo therapy and repeated
after 6months.
BONE MARROW
A total of 40–80mL of bone marrow was aspirated from the pos-
terior iliac crest under local anesthesia in the morning of the PCI
day. Mononuclear cells were isolated using Ficoll-Hypaque gradi-
entcentrifugation,andwerewashed,suspended,ﬁltered,subjected
to quality-control,and counted for CD34+ cells as described ear-
lier (Huikuri et al., 2008). The BMC separation procedure took
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Table 1 | Characteristics of the patients.
BMC (n =11) Control (n =8) p
Male gender, n (%) 11 (100%) 8 (100%) 1.00
Age, years 56±12 55 ±9 0.89
Body mass index, kg/m2 26 (26–28) 26 (24–27) 0.49
Hypertension, n (%) 5/11 (45%) 2/8 (25%) 0.63
Hypercholesterolemia, n (%) 3/11 (27%) 3/8 (38%) 1.00
Diabetes mellitus, n (%) 1/11 (9%) 0/8 (0%) 1.00
Current smoking, n (%) 3/11 (27%) 3/8 (38%) 0.61
SEVERITY OF CAD n (%)
Previous AMI 2 (18%) 1 (13%) 1.00
Previous angina pectoris 1/11 (9%) 2/8 (25%) 0.55
1-Vessel disease 5/11 (46%) 5/8 (63%) 0.65
2-Vessel disease 4/11 (36%) 3/8 (38%) 1.00
3-Vessel disease 2/11 (18%) 0/8 (0%) 0.49
INDEX EVENTAND PERCUTANEOUS CORONARY INTERVENTION
Symptoms to thrombolysis time, hours 2.0 (1.2) 2.9 (2.0) 0.27
Highest troponin value, μg/L 2.3 (0.7–3.8) 1.0 (1.0–2.0) 0.37
From reperfusion to study therapy, days 3.2 (1.0) 3.1 (1.2) 0.84
Infarct-related artery, n (%)
LAD 3/11 (27%) 4/8 (50%) 0.38
LCX 2/11 (18%) 3/8 (38%) 0.60
RCA 6/11 (55%) 1/8 (13%) 0.15
Target lesion stenosis, % 80 (60–94) 70 (59–99) 0.34
TIMI FLOW BEFORE PCI
0 2/11 (18%) 0/8 (0%) 0.49
1 2/11 (18%) 2/8 (25%) 1.00
2 0/11 (0%) 2/8 (25%) 0.16
3 7/11 (64%) 4/8 (50%) 0.66
TIMI FLOWAFTER PCI
3 11/11 (100%) 8/8 (100%) 1.00
Drug-eluting stents 11/11 (100%) 8/8 (100%) 1.00
GPIIb/IIIa inhibitor during acute PCI 2/11 (18%) 1/8 (13%) 1.00
LEFTVENTRICULAR PARAMETERS BYANGIOGRAPHY BEFORE STUDYTHERAPY
EF , % 66.9±5.2 55.1±18.3 0.15
EDV, mL 161±48 154±32 0.74
ESV, mL 57 .0 (38.5–61.7) 53.6 (46.6–86.4) 0.44
STUDYTHERAPY
Amount of injected CD34+ *1 0 6 2.9±2.0 placebo NA
Viability of cells, % >95% – NA
CARDIAC MEDICATIONAT DISCHARGE, n (%)
Aspirin 11/11(100%) 8/8 (100%) 1.00
Clopidogrel 11/11(100%) 8/8 (100%) 1.00
β-Blocker 10/11 (91%) 8/8 (100%) 1.00
ACE inhibitor or ATII blocker 9/11 (82%) 7/8 (88%) 1.00
Statin 11/11(100%) 8/8 (100%) 1.00
Diuretics 1/11 (9%) 6/8 (75%) 0.006
Nitrate 5/11 (46%) 2/8 (25%) 0.63
Calcium antagonists 0/11 (0%) 0/8 (0%) 1.00
Digitalis 1/11 (9%) 4/8 (50%) 0.11
CARDIAC MEDICATIONAT 6MONTH FOLLOW-UP , n (%)
Aspirin 11/11 (100%) 8/8 (100%) 1.00
Clopidogrel 10/11 (91%) 8/8 (100%) 1.00
β-Blocker 10/11 (91%) 8/8 (100%) 1.00
(Continued)
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Table 1 | Continued
BMC (n =11) Control (n =8) p
ACE inhibitor or ATII blocker 9/11(82%) 7/8 (88%) 1.00
Statin 11/11(100%) 8/8 (100%) 1.00
Diuretics 1/11(9%) 2/8 (25%) 0.55
Nitrate 1/11(9%) 2/8 (25%) 0.55
Calcium antagonists 0/11 (0%) 0/8 (0%) 1.00
Digitalis 0/11 (0%) 0/8 (0%) 1.00
Continuousvariableswithnormaldistributionareexpressedasmean±SDandwithanon-parametricdistributionasmedian(lower-upperquartile),categoricalvariables
as frequency (percent). Independent sampleT-test combined to Levene’s test were applied for continuous variables with normal distribution, and Mann–Whitney U
test for variables with non-parametric distribution. Chi-square/Fisher’s exact test was used for categorical variables as appropriate. All tests were performed two-
tailed. CAD, coronary artery disease; AMI, acute myocardial infarction; LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery; RCA,
right coronary artery; PCI, percutaneous coronary intervention; GP , glycoprotein; EF , ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; ACE,
angiotensin-converting enzyme; AT, angiotensin receptor.
about3handthecellswerekeptin+4˚Cuntilintracoronaryinjec-
tion was performed within 3h after the procedure. The isolated
BMC’sfunctionalcapacitywasconﬁrmedbyahighmeannumber
of 450granulocyte–macrophage colony-forming units/plate. The
placebocontainedthepatient’sownserumandheparinizedsaline.
CARDIAC PET
All imaging studies were performed after the subject had fasted
for6handavoidedalcoholandcaffeinefor12h.Heartrate,blood
pressure, and ECG were monitored throughout the studies. The
positron-emitting tracers [11C]HED, [15O]H2O, and [18F]FDG
(Hamacher et al., 1986; Någren et al., 1995; Sipilä et al., 2001)
were used with PET (GE Discovery STE System; GE Medical
Systems, Milwaukee, WI, USA) and image acquisition protocols
as previously described (Nuutila et al., 1995; Mäki et al., 1996;
Koskenvuoetal.,2001;Pietiläetal.,2002).Thesubjectswerelying
in a supine position throughout the study. The total imaging time
in the PET camera was 2h and 20min/time-point. All PET data
were corrected for dead time, decay, and measured photon atten-
uation. Images were reconstructed with standard algorithms. The
PETimageswerequantitativelyanalyzedusingCarimas™software
(Nesterov et al.,2009) by two experienced readers blinded to ther-
apyandotherresults.ThetotalradiationdosefromthePETstudies
was 15.4mSv.
Carbon-11 labeled hydroxyephedrine ([11C]HED) is a false
norepinephrine analog developed for the evaluation of presynap-
tic sympathetic innervation (Rosenspire et al., 1990; Schwaiger
et al., 1990). [11C]HED shares the same uptake-1 and vesicular
storage mechanisms with norepinephrine. The relative stability
of [11C]HED makes it a suitable agent for mapping sympathetic
neurons in the human heart. A bolus of [11C]HED (517MBq,
equivalenttoradiationdoseof1.1mSv)wasinjectedintravenously
over 60s and a dynamic emission scan was acquired for 40min.
[11C]HEDstudieswereanalyzedusingtheretentionindexmethod
(Pietilä et al.,2002).
Oxygen-15 labeled water was produced using a diffusion
membrane technique in a continuously working water module
(Hidex Radiowater Generator, Hidex Oy, Turku, Finland; Sip-
ilä et al., 2001). To measure myocardial perfusion, [15O]H2O
(950MBq, equivalent to radiation dose of 0.9mSv, given twice
per time-point) was injected over 15s at an infusion rate of
10mL/min. A dynamic scan was performed for 4min 40s
(14×5s,3×10s, 3×20s, and 4×30s). After decay of the 15O
radioactivity(10min),thesecond[15O]-H2Oscanwasperformed
during adenosine (140μg/min/kg) induced stress.Adenosine was
started 2min before the start of the scan and infused for a total
of 6min 40s. The coronary ﬂow reserve (CFR) was deﬁned as
the ratio of myocardial perfusion during adenosine infusion to
perfusion at baseline.
To stabilize metabolic conditions for imaging euglycemic, an
insulinclamp(1mU/kg/min)wasapplied60minbeforetheFDG-
PET-study and continued until the end of the study (DeFronzo
etal.,1979).Duringhyperinsulinemia,normoglycemiawasmain-
tained using 20% glucose infusion adjusted according to plasma
glucoselevelsdeterminedevery5–10minfromarterializedvenous
blood.Oncesteadystatewasachieved,[18F]FDG(255MBq,equiv-
alent to a radiation dose of 4.8mSv) was injected and a dynamic
scan was performed for 62min giving 26 frames (12×15s,
4×30s,2×120s,1×180s,4×300s,and3×600s).Arterialized
venoussamplesweredrawntomeasureradioactivityandcalculate
the input function for Patlak analysis.
DETERMINING AREA AT RISK AND REFERENCE AREA
For all imaging data, the LV was divided into 17 segments
(Cerqueira et al., 2002). After blinded analysis of angiography,
PET, and MRI, the myocardial segments were classiﬁed as belong
either to area at risk or reference area according to the culprit
lesion in the ﬁrst angiography, but also considering wall motion
abnormalities in the ﬁrst MRI and echocardiography (results not
shown).Thesegmentswereclassiﬁedbyconsensusoffourreaders.
In each patient the sum of segments behind the culprit lesion in
the infarct-related artery was determined as the area at risk. The
reference area was the sum of segments outside the area at risk
not showing any wall motion abnormality. Segments with wall
motion abnormality observed outside the myocardium supplied
by the culprit artery were excluded from further analysis to avoid
using areas of an old MI as reference areas. This individual cate-
gorization into area at risk and reference area was applied for all
MRI and PET studies, both day 10–15 and 6months after BMC
therapy.
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CALCULATING AREA AT RISK (RATIO), PERFUSION RESERVE, PET
DEFECT SIZE, AND BMC TREATMENT EFFECT
Positron emission tomography data were analyzed quantitatively
on 17 segmental bases. Thereafter, segmental PET values in an
area at risk or in reference area were summed and divided by the
number of segments belonging to that area. This individual mean
PET value in an area at risk was normalized (to be comparable
with others) by dividing it by the mean value in the reference
area. These normalized PET values,namely area at risk (ratio) are
presentedinTable 2.Perfusionreserveinanareaatriskwascalcu-
lated by dividing adenosine ﬂow by resting ﬂow. To calculate PET
defectsize,polarmapsgeneratedwithCarimas™softwarev.1were
opened in the ImageJ (v.1.42q) environment (Rasband, 2009). To
assessthedefectsizeinPET,valueslessthan70%of themaximum
were determined as positive for defect, and the size was expressed
as a ratio of the defect’s size to the size of the whole LV. The basal
halves of the posterior septal segments were not included into the
defect area. The effect of treatment was deﬁned as the difference
between defect sizes at 6month’s and day 10–15 after therapy,
so that negative numbers correspond to beneﬁcial effects of the
treatment.
CARDIAC MRI
All subjects underwent a MRI study at 1.5T (Philips Gyroscan
Intera Nova Dual MR, Philips Medical Systems, Best, The
Netherlands) with a phased-array torso coil and a vector cardio-
graphic method for ECG-gating. All acquisitions were obtained
during breath holding in mid inspiration. Each MRI study con-
sisted of cine imaging of both ventricles for volumetrics and wall
motion at rest. Late enhancement (LE) imaging was applied for
scar assessment. MRI cine frames were analyzed ofﬂine with com-
mercial software (ViewForum 2003 release 4.1, Philips Medical
Systems, Best, The Netherlands). An experienced reader, blinded
to therapy,analyzed all MRI exams.
Theleftandrightventricleswerecoveredby8–12slicesatshort
axis (SA) orientation using a balanced turbo ﬁeld echo (bTFE)
pulse sequence. Additionally, at least six slices were acquired
both in four-chamber and two-chamber orientations. Visual wall
motion analysis was performed using a 17-segment model of
the LV (Cerqueira et al., 2002), and each segment was visually
graded as normal (1), hypokinetic (2), akinetic (3), dyskinetic
(4), or aneurysmal (5). To calculate the wall motion score index
(WMSI), these segmental numbers in the area at risk or refer-
ence area were summed and divided by the number of segments
belonging to that area. Volumetrics were analyzed according to
our previous validation (Koskenvuo et al., 2007), where LV end-
diastolic volumes (EDV) and end-systolic volumes were indexed
tobodysurfacearea(LVEDVIandLVESVI).bTFEpulsesequences
wereusedwiththefollowingparameters:retrospectivegating,rep-
etition time/echo time (TR/TE) 3.4/1.2ms, ﬂip angle 60˚, FOV
T a b l e2|E f f e c to fmononuclear stem cell therapy on myocardial innervation, perfusion, metabolism, and infarct size measured by cardiac PET
and MRI.
Day 10–15 p Day 180 p Δ Day 180 – Day 10–15 p
MYOCARDIAL INNERVATION ([11C]HED-PET)
HED-retention index in area at risk (ratio) BMC 0.89±0.10 0.06 0.94±0.07 0.02 0.06±0.08 0.31
Control 0.73±0.19 0.75±0.19 0.02±0.08
HED-defect size (%) BMC 14.9±9.4 0.10 10.0±7 .8 0.04 −4.9±4.0 0.08
Control 26.1±14.2 24.5±14.5 −1.6 ±2.2
MYOCARDIAL PERFUSION ([15O]H2O-PET)
Rest perfusion in area at risk (ratio) BMC 0.93±0.15 0.62 0.84±0.22 0.18 −0.09±0.17 0.03
Control 0.89±0.20 0.99±0.25 0.10±0.17
Stress perfusion in area at risk (ratio) BMC 0.83±0.16 0.90 0.91±0.20 0.75 0.08±0.29 0.88
Control 0.81±0.29 0.88±0.21 0.06±0.17
Perfusion reserve in area at risk (ratio) BMC 1.96±1.01 0.18 1.62±0.85 0.84 −0.33±1.58 0.15
Control 1.27±1.07 1.70±0.80 0.43±0.34
MYOCARDIAL METABOLISM ([18F]FDG-PET)
FDG uptake in area at risk (ratio) BMC 0.77±0.09 0.47 0.84±0.12 0.04 0.06±0.09 0.07
Control 0.71±0.22 0.66±0.22 −0.05±0.16
FDG-defect size (%) BMC 16.2±8.3 0.44 12.8±10.6 0.27 −3.3±6.7 0.52
Control 21.1±14.5 19.6±14.8 −1.5 ±3.4
INFARCT SIZE (LATE ENHANCEMENT Gd-DTPA MRI)
Infarct size (g) BMC 6.7±4.3 0.08 7 .0±7 .2 0.15 0.4±4.2 0.047
Control 24.4±22.3 19.3±17.6 −5.1±5.9
Infarct size (% of LV mass) BMC 5.0±3.1 0.08 5.4±5.8 0.15 0.4±3.6 0.045
Control 19.3±17 .5 14.0±13.3 −5.3±6.7
[
11C]HED, carbon-11 labeled hydroxyephedrine; [
15O]H2O, oxygen-15 labeled water; [
18F]FDG, ﬂuorine-18 labeled ﬂuoro-2-deoxy-d-glucose.Tracer activity ratios were
calculated in each patient by dividing PET measurement in the area at risk with corresponding value in the reference area. BMC and placebo groups were compared
using independent sample t-test combined to Levene’s test.
www.frontiersin.org January 2012 | Volume 3 | Article 6 | 5Mäki et al. Stem cell therapy for MI
320–360mm,acquisitionmatrix192×256,reconstructionmatrix
256×256, rFOV 100%, 30phases/cardiac cycle, slice thickness
6.0mm,and gap 0mm.
A phase-sensitive inversion recovery T1–TFE pulse sequence
wasappliedforLEimaging10minafterinjectinggadoteratemeg-
lumine (Dotarem 279.3mg/mL, Guerbet, Roissy CdG, France)
with a dose 0.3mmol/kg. The following imaging parameters were
used: prospective gating, TR/TE 4.0/1.2ms, ﬂip angle 15˚, acqui-
sition matrix 168×256, reconstruction matrix 256×256, FOV
320–360mm,rFOV 100%,8–15 slices/breath hold,slice thickness
6mm, and gap 0mm. TI was optimized individually using a TI-
scoutsequence.ThewholeLVwascoveredbyLEimagesatSAori-
entation, and at least eight additional slices were acquired in both
two-andfour-chamberorientationtomakeiteasiertodistinguish
healthymyocardiumfromscar.Thescarmasswasmeasuredquan-
titativelyfromLEingramsasshownearlier(Mewtonetal.,2011).
STATISTICAL ANALYSES
The Shapiro–Wilk test was applied to determine whether that
data are normally distributed. Normally distributed, continu-
ous variables are expressed as mean±SD and non-parametric as
median,andlowerandupperquartiles.Allcategoricalvariablesare
depicted using relative frequency distributions. Characteristics of
treated patients and controls were compared using the chi-square
testforcategoricalvariablesifappropriate,otherwiseFisher’sexact
test was used. Independent samples t-tests combined with Lev-
ene’s tests were used to test the signiﬁcance of differences between
groups for all continuous variables and Mann–Whitney U tests
were used for non-parametric variables. Differences were consid-
ered signiﬁcant if the two-sided p-value was <0.05. All analyses
were performed using SPSS software package (Version 16.0; SPSS,
Inc., Chicago, IL, USA).
RESULTS
PATIENT GROUPS
Bonemarrowcellandcontrolgroupswererelativelywellbalanced
according to age, BMI, risk factors/concomitant disease, severity
of coronary artery disease, and medication both at discharge and
6month time-point (Table 1). Three patients had had earlier MI,
two from BMC group, and one from control group. One patient
in each group had the earlier infarct in the current culprit artery
whereas one patient’s infarct (BMC group) located in the other
segmentsandthosewereexcludedfromtheﬁnalanalysis.Thedif-
ferencesexistedatbaselineuseof diuretics,whichwas9%inBMC
group and 75% in controls (p =0.006).
THERAPY IN GENERAL
BMC therapy failed to demonstrate consistently better recovery
from MI compared to placebo at 6months follow-up. The jeop-
ardized myocardium behind the infarct-related artery, namely
area at risk, consisted of 6.1 segments on average per patient,
of which 4.4 segments had a wall motion abnormality. Fourteen
out of 323 myocardial segments were excluded from ﬁnal analysis
because wall motion abnormality was not related to the culprit
lesion (probably corresponding to the old MI or other signiﬁcant
coronary stenosis).
PET PARAMETERS
The positron-emitting tracer [11C]HED retention index and
[18F]FDG uptake in the area at risk describe the depth of
myocardialinjury,whereasdefectsizesassesstheextentof damage
with respect to the whole LV (infarct expansion). Table 2 presents
detailed PET results.
MYOCARDIAL INNERVATION BY PET
[11C]HED-retention index in the area at risk did not improve
more in the BMC group vs. controls during follow-up
(0.06±0.08 vs. 0.02±0.08, p =0.31). However, there was a
trend of more decrease in [11C]HED defect size (%) in
the BMC-treated group compared to controls (−4.9±4.0 vs.
−1.6±2.2%, p =0.08). Figure 2 shows examples of [11C]HED
polar plots from a control patient and two patients treated with
BMCs.
FIGURE2|P olar plots of [
11C]HED–PET studies at 1–2weeks and
6months after placebo or BMC therapy. (A)The patient with placebo
treatment had no clear improvement at 6months, (B) improvement in
[
11C]HED retention index in BMC-treated patient, and (C) slight
improvement [
11C]HED retention index in a patient with BMC therapy which
was not as evident as in previous patient (B).
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MYOCARDIAL PERFUSION BY PET
Perfusionmeasuredby[15O]H2O-PETdidnotdifferintheareaat
risk,inrestorstressatanday10–15time-pointbetweenBMCand
placebogroups(p =0.62andp =0.90).However,restperfusionin
the area at risk adjusted to reference area decreased during follow-
up in the BMC group and slightly increased in the placebo group
(−0.09±0.17 vs. 0.10±0.17, p =0.03). A small, non-signiﬁcant
decreaseinperfusionreserveintheareaatriskwasobservedinthe
BMC group compared to controls (−0.33±1.58 vs. 0.43±0.34,
p =0.15) during follow-up.
MYOCARDIAL GLUCOSE METABOLISM BY PET
[18F]FDG uptake ratio or defect size at baseline did not dif-
fer between the BMC group and control group (0.77±0.09 vs.
0.71±0.22, p =0.47 and 16.2±8.3 vs. 21.1±14.5, p =0.44). At
6month’s,the[18F]FDGuptakeratiowashigherintheBMCgroup
than in the control group (0.84±0.12 vs. 0.66±0.22, p =0.04,
respectively) and a trend of increasing glucose metabolism was
found in the area at risk in the BMC group (p =0.07). However,
the decrease in FDG-defect size was not different between the
groups (p =0.52). Figure 3 shows examples of [18F]FDG polar
plots from a control and two BMC-treated patients (patients are
the same as in Figure 2).
INFARCT SIZE, CARDIAC FUNCTION, AND MORPHOLOGY BY MRI
At LE MRI, the mean scar mass was 6.7±4.3g in the BMC
group and 24.4±22.3g in controls at the day 10–15 time-point
(p =0.08) indicating a trend of slightly larger scars in the con-
trol group at day 10–15 phase. The scar mass decreased more
in the control group than in the BMC group during 6month
follow-up (−5.1±5.9 vs. 0.4±4.2g,p =0.047),possibly because
alargerscarsizeenablesmorerecoveryduringfollow-up.Figure4
showsLEMRIimagesfromBMC-treated(Figure4A)andcontrol
(Figure 4B) patients at 1–2week and 6month time-points. LVEF
was53.6±6.3%inBMCand51.7±12.7%incontrolsat6months
(p =0.71), indicating ejection fraction (EF) increases of 0.5±3.7
and 2.9±6.4% (p =0.37) after ﬁrst MRI evaluation (Table 3).
A trend of less LV remodeling in the BMC group was observed
whenestimatedbychangesinLVend-diastolic(p =0.12)andend-
systolic (p =0.19) volume indices at follow-up. Examples of cine
MRI images are shown from a BMC-treated patient at 1–2week
(Online Resource 1) and at 6month (Online Resource 2) time-
points and from a control patient at 1–2week (Online Resource
3) and at 6month (Online Resource 4) time-points. A decreasing
trendofcardiacindexwasdetectedintheBMCgroupcomparedto
controls (−0.2±0.4 vs. 0.4±0.7L/min/m2,p =0.06). In the area
at risk a systolic function parameter, namely WMSI, improved
(decreased; −0.05±0.23 vs. −0.09±0.20) in BMC, and placebo
groups at follow-up but neither therapy was better than the other
(p =0.73). No signiﬁcant differences were observed between the
groups in terms of right ventricular EF or volumes. Detailed data
on the functional effects of BMC therapy on left and right heart
are presented in Tables 3 and 4.
DISCUSSION
While several studies have investigated the effects of intracoro-
nary BMC therapy on global LV function and hemodynamics,
FIGURE3|P olar plots of [
18F]FDG-PET studies at 1–2weeks and
6months after placebo or BMC therapy.The patients are the same as in
Figure 2. (A)The patient with placebo treatment has a large defect in the
LAD region.The defect size is slightly reduced (34–27%) at 6months, (B) a
patient with BMC therapy has a moderate size defect in the LAD region at
day 10–15 time-point, and the defect size was clearly reduced at 6months
follow-up (21–2%), and (C) a patient with BMC therapy has a moderate size
defect in the LAD region and no clear change in the defect size (26–22%)
was observed at 6months follow-up.
the present study is the ﬁrst to evaluate the mechanistic insights
and effects of BMCs on infarct-related myocardium by determin-
ing changes in perfusion, metabolism, innervation, and cardiac
function occurring from the early initial phase to 6months there-
after.Somerecoveryinjeopardizedmyocardiumwasalsodetected
without BMCs, indicating the importance of the placebo-treated
control group. The main effects of BMCs detected in the present
study can be summarized as follows: (1) a trend of more decrease
in the size of denervated myocardium; (2) minor enhancement
of glucose metabolism in the area at risk; (3) potentially positive
effect on LV remodeling; (4) mild negative effect on scar size and
myocardial perfusion reserve in the area at risk. Thus, there were
no gross differences in recovery between BMC and control groups
at6monthsafteracuteSTEMIwithrespecttonumerousmeasured
parameters.
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FIGURE 4 | (A,B) Late enhancement MRI images at 1–2weeks and 6months
after placebo or BMC therapy. Late enhancement MRI images from (A) BMC
and (B) placebo treated patients at day 10–15 (1–2weeks) and 6months
time-points. Patient (A) had infarct size 8.8% at day 10–15 time-point and
11.3% at 6months, and patient (B) infarct size was 40.3 and 31.6% at
corresponding time-points.
EFFECT OF BMC THERAPY ON MYOCARDIAL INNERVATION
Reduced myocardial [11C]HED retention is associated with poor
prognosis in chronic heart failure and it is even suggested that
[11C]HED uptake is a better predictor of death than more com-
mon predictors of outcome such as EF or heart rate variability
(Pietiläetal.,2001;LinkandCaldwell,2008).Ourstudyevaluated
for the ﬁrst time the effect of stem cell therapy on cardiac inner-
vation. [11C]HED uptake improved in both groups at 6month
follow-up following acute MI but BMC therapy was not superior
to placebo (p =0.31). However, we observed a positive trend of
decreasing [11C]HED defect size in the BMC group (−4.9±4.0
vs. −1.6±2.2,p =0.08).
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T a b l e3|E f f e c to fmononuclear stem cell therapy in left ventricular function assessed by cardiac MRI and X-ray angiography.
Baseline Day 10–15 Day 180 Δ Day 10–15 vs. baseline Δ Day 180 vs. baseline Δ Day 180 vs. Day 10–15
LEFTVENTRICULAR EJECTION FRACTION (%)
BMC 66.9±5.2 53.1±7 .0 53.6±6.3 −13.8±7. 8 −13.2±7 .4 0.5±3.7
Control 55.1±18.3 48.9±11.8 51.7±12.7 −6.3±7. 6 −3.4±9.4 2.9±6.4
p-Value 0.15 0.42 0.71 0.07 0.03 0.37
LEFTVENTRICULAR END-DIASTOLICVOLUME INDEX (mL/m2)
BMC 78.0±17 .0 83.4±19.2 79.0±17 .5 5.4±21.7 1.0±20.1 −4.4±13.3
Control 77 .8±20.2 87 .3±14.7 95.3±24.0 9.5±29.0 17 .4±38.6 8.0±16.7
p-Value 0.99 0.66 0.14 0.75 0.29 0.12
LEFTVENTRICULAR END-SYSTOLICVOLUME INDEX (mL/m2)
BMC 25.6±6.0 39.7±13.4 37 .2±12.7 14.1±11.1 11.5 ±11.6 −2.5±5.0
Control 33.7±14.8 45.5±15.7 47 .6±21.6 11.8±11.9 13.9±17 .9 2.1±8.2
p-Value 0.22 0.44 0.25 0.70 0.75 0.19
Left ventricular ejection fraction and volumes were measured using X-ray angiography at baseline (3days post-MI, the day of therapy) and using cardiac MRI at day
10–15 and day 180 time-points after BMC (bone marrow mononuclear stem cell) therapy. All data is presented as mean±SD. Independent sample t-test was used
for comparison.
T a b l e4|E f f e c to fmononuclear stem cell therapy on left and right ventricular parameters measured by cardiac MRI.
Day 10–15 p Day 180 p Δ Day 180-early p
LEFTVENTRICLE
LV stroke volume index (mL/m2) BMC 43.6±8.4 0.53 41.8±6.0 0.45 −1.8 ±9.3 0.28
Control 41.1±19 45.3±11.2 4.2±12.6
LV cardiac index (L/min/m2) BMC 2.3±0.4 0.84 2.1±0.2 0.04 −0.2±0.4 0.06
Control 2.3±0.5 2.7±0.7 0.4±0.7
LV mass index (g/m2) BMC 66.2±12.4 0.83 66.2±6.8 0.32 0.0±10.3 0.24
Control 65.0±8.8 70.7±11.4 5.7±9.1
WMSI area at risk (score) BMC 1.67±0.41 0.054 1.61±0.39 0.06 −0.05±0.23 0.73
Control 2.26±0.74 2.17±0.72 −0.09±0.20
WMSI remote zone (score) BMC 1.06±0.12 0.89 1.03±0.06 0.95 −0.04±0.12 0.93
Control 1.06±0.09 1.02±0.10 −0.03±0.10
RIGHTVENTRICLE
RV–EF (%) BMC 62.1±8.0 0.95 59.5±8.3 0.53 −2.6±9.1 0.64
Control 61.8±8.4 61.7±5.7 −0.1±12.2
RV–EDVI (mL/m2) BMC 74.2±28.1 0.35 68.4±10.5 0.30 −5.8±23.6 0.12
Control 63.9±10.9 75.5±16.5 11.5±19.2
RV–ESVI (mL/m2) BMC 28.3±13.0 0.63 28.6±8.8 0.95 0.3±6.0 0.44
Control 25.9±5.1 28.9±6.9 3.0±7. 7
LV, left ventricle; BMC, bone marrow cell;WMSI, wall motion score index; RV, right ventricle; EF , ejection fraction; EDVI, end-diastolic volume index; ESVI, end-systolic
volume index. All data is presented as mean±SD. Independent sample t-test was used for comparison.
EFFECT OF BMC THERAPY ON MYOCARDIAL PERFUSION
The effect of BMC therapy on myocardial perfusion in the setting
of acute MI has mostly been evaluated with SPECT (Strauer et al.,
2002; Dobert et al.,2004; Bartunek et al.,2005; Lunde et al.,2006;
Beeres et al.,2007;Meluzín et al.,2008). These studies show either
reduction of perfusion defect (Strauer et al., 2002; Dobert et al.,
2004; Bartunek et al., 2005) or unchanged perfusion improve-
ment compared to controls (Lunde et al., 2006; Meluzín et al.,
2008).However,theonlystudyusingPETforthequantiﬁcationof
myocardialperfusionshowednodifferencebetweenBMC-treated
patientsandcontrolsat4monthsfollow-up(Janssensetal.,2006),
which is consistent with our study. CFR provides insight into
the integrity of both the epicardial conduit arteries and distal
microvascularbed.TheREPAIR-AMIsubstudyshowedthatBMC
therapywasassociatedwithcompleterestorationof intracoronary
Doppler derived CFR (Erbs et al., 2007). However, coronary ﬂow
measurement may be misleading when fast deceleration time is
not taken into account and a subtraction is not performed for
reverse ﬂow existing in late diastole due to permanent MI induced
capillary damage (Saraste et al., 2007). Conversely, BMC therapy
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hadnoeffectonPETmeasurementof perfusionreserveinthearea
at risk in our study nor in a larger placebo-controlled study with
intracoronary infusion of mobilized peripheral blood stem cells
(Kang et al.,2006).
EFFECT OF BMC THERAPY ON MYOCARDIAL METABOLISM, VIABILITY,
AND INFARCT SIZE
A total of ﬁve studies (including 128 patients) have used PET
for evaluating the effect of stem cell therapy on FDG metabo-
lism/viability in the setting of acute MI (Assmus et al.,2002;Chen
et al.,2004; Dobert et al.,2004; Bartunek et al.,2005; Balogh et al.,
2007; Beeres et al., 2007). Four of these studies used PET imaging
only for BMC-treated patients and one had no baseline evalua-
tion. All of these studies demonstrated increased 18F-FDG uptake
in the infarct zone at 4–6months follow-up. Our study showed
a trend of improved 18F-FDG uptake in the area at risk dur-
ing 6months follow-up in the BMC group compared to placebo
(p =0.07),butFDG-defectsizewascomparableinthetwogroups
(p =0.52). Late-enhancement MRI describes viability in an alter-
nativeway,bydetectingnon-viablemyocardiumwiththeprinciple
of“bright is dead,”which is regarded the most accurate technique
for myocardial scar assessment. There are four earlier randomized
studies with serial LE imaging after stem cell therapy for acute MI
(Janssens et al., 2006; Lunde et al., 2006; Meyer et al., 2006; Dill
etal.,2009).Janssensetal.(2006)demonstratedareductionofscar
size with BMCs (2.3g more in a BMC group, p =0.036) whereas
the BOOST or REPAIR-AMI studies found no beneﬁt of BMC
therapy regarding scar size (Meyer et al., 2006; Dill et al., 2009).
Notably,theASTAMIstudyshowedatrendof morescarreduction
in placebo vs. BMC group (treatment effect −3.9mL, p =0.07;
Lundeetal.,2006).Thelatter,negativeﬁndingsaremainlyconsis-
tent with our results as we found a trend of more scar reduction
in the control group (−5.1±5.9 vs. 0.4±4.2g p =0.047). How-
ever, in this regard, a trend of larger infarcts in the control group
(indicated by insigniﬁcantly lower EFs at baseline angiography
and day 10–15 MRI) makes it more likely to also see more infarct
reduction in the group with larger infarct. Regarding scar size
measurements in our study, BMC therapy failed to demonstrate
any beneﬁt; the only change was the minor enhancement of glu-
cose metabolism in the area at risk, which has uncertain clinical
value.
EFFECT OF BMC THERAPY ON MYOCARDIAL FUNCTION AND
REMODELING
MRI derived LV EFs were determined at day 10–15 and 6months
after intracoronary BMC transfer. X-ray cine angiography is likely
to measure almost 9% higher EFs compared to MRI (Kondo
et al., 2003) and therefore observed difference between EF in X-
ray angiography at baseline to EF at day 10–15 MRI is mainly
due to methodological differences and the relatively high base-
line EF do not indicate very small MIs in this study. From day
10–15 to 6months EF increase was not signiﬁcant between the
groups (0.5±3.7% in BMC and 2.9±6.4% in the control group,
p =0.37). Three recent meta-analyses applying different imaging
methods for estimating changes in global EF after BMC ther-
apy demonstrated improvements of 3.0, 3.7, and 4.8% (absolute
change) in EF compared to the control group but not for EDV
(p =0.11, p =0.39, and p =0.41), which is a good measure of
remodeling following MI (Abdel-Latif et al., 2007; Lipinski et al.,
2007; Zhang et al., 2009). In many studies, echocardiography or
angiography have been used for volumetric measurement, which
is considered as a limitation when evaluating a small group of
patients due to reproducibility issues. Cardiac MRI, as used in
the current study, is the golden standard for determining ven-
tricular volumes and EF. A total of eight randomized controlled
studies (including 539 patients) have previously evaluated LV
function and volumetrics using MRI after stem cell therapy for
acute MI (Wollert et al., 2004; Janssens et al., 2006; Kang et al.,
2006; Lunde et al., 2006; Meyer et al., 2006; Beeres et al., 2007;
Dill et al., 2009; Hare et al., 2009). Only 3 of the 8 studies with
serial cardiac MRI demonstrated improvement in global EF; (1)
difference to placebo 6% (p =0.0026; Wollert et al., 2004), (2)
5.3% (p =0.046) at 6months follow-up (Kang et al., 2006), and
(3) difference to placebo 3.4% at 12month follow-up,p =0.003),
whereas no improved EF was observed at 6months and no sig-
niﬁcant effects on LV volumes at any time-point (Hare et al.,
2009). Furthermore, none of the remaining ﬁve studies demon-
strated positive trends (treatment effect >2% with a p <0.15)
toward better EF in the BMC group and only one study detected
signiﬁcant improvements in end-diastolic/systolic volume (ESV’s
difference to placebo 11.9mL,p =0.04; Kang et al.,2006). One of
the studies demonstrated a trend of lower EF in BMC group vs.
placebo (difference 3.1%, p =0.054; Lunde et al., 2006). Regard-
ing EFs, our results are similar to observations by Janssens et
al. and Lunde et al., and are at least partially explained by rela-
tively fast reperfusion therapy. In these studies, the ﬁrst reperfu-
sion therapy was given within 4h following acute STEMI and
therefore may have resulted in a smaller infarct size and only
modestly compromised EF at baseline as also observed in our
study (Janssens et al., 2006; Lunde et al., 2006). In the REPAIR-
AMI sub-study, the magnitude of LV contractile recovery was
inversely related to the baseline EF and in the studies by Ten-
dera et al. and Dill et al. the increase in EF in the BMC group was
limited to patients with more depressed EFs (Schachinger et al.,
2006a; Dill et al., 2009; Tendera et al., 2009). The REPAIR-AMI
sub-study showed a trend of improved EF, EDV, and ESV (dif-
ferences to placebo; 2.8%, p =0.26; 14mL, p =0.12; and 13mL,
p =0.08), respectively (Dill et al., 2009). In our study, a trend
(p =0.12) of LVEDVI improvement was observed in the BMC
group (−4.4mL/m2) at 6months compared to the control group
(8.0mL/m2).
To overcome the insensitivity of global parameters of LV func-
tion, regional function was estimated using WMSI both in the
area at risk and reference area. A slight improvement in WMSI
was observed in the BMC and control groups within the mea-
sured time course, but no signiﬁcant difference between the
groups was found (p =0.73). There are no earlier studies eval-
uating RV function following stem cell therapy for acute MI
(some infarcts may extend into the right heart but this was not
conﬁrmed by LE imaging). Our study showed that BMC ther-
apy had no remote effects on right heart function in this patient
population.
Frontiers in Physiology | Clinical andTranslational Physiology January 2012 | Volume 3 | Article 6 | 10Mäki et al. Stem cell therapy for MI
BMC TRANSPLANTATION
According to a recent review of cardiac stem cell therapy in
humans, neither the number of transplanted cells, nor cell type
(bone marrow derived mononuclear vs. mesenchymal or circulat-
ing peripheral progenitor) had a signiﬁcant effect on changes in
EF or infarct size (Abdel-Latif et al., 2007). Interestingly, recent
animal study proposed that mononuclear BMCs survive better at
ischemic milieu compared to mesenchymal stem cells (van der
Bogt et al.,2008) and in our study,mononuclear BMCs were used
for therapy. However, so far the majority of transplanted cells die
within 1–2months after transplantation (Amsalem et al., 2007;
van der Bogt et al., 2009), which is concordant with our ﬁnding
that no major changes in cardiac parameters were detected during
follow-upwhencomparedtocontrols.Ithasbeenstatedthatpoor
survival pattern makes robust repopulation impossible and also
limits protective paracrine action of the cells (van der Bogt et al.,
2009).
The timing of cell delivery may also be important. In this
study, BMCs were transferred 3days after primary thrombolysis.
The optimal time for cell delivery after myocardial infarction is
unknown, but according to previous studies it has only a minor
inﬂuence on outcome in the setting of acute MI (Bartunek et al.,
2006; Abdel-Latif et al., 2007). Intracoronary cell infusion is used
in most of the clinical studies for cell delivery and therefore it is
unlikely to explain conﬂicting results between the studies. More-
over, intracoronary single-bolus BMC therapy is reported to be
as effective as balloon-occlusion cell delivery (Doyle et al., 2007).
Cell preparation and storage may also partly inﬂuence the dis-
crepantresultsbetweenthestudies.Inthepresentstudy,theBMCs
wereinjectedimmediatelyafterthebonemarrowaspirationwith-
out storage and the colony-forming function of the cells was
conﬁrmed.
LIMITATIONS
A distinct difference between the present and previous studies
is that we included patients treated with thrombolysis followed
by later PCI, whereas all prior trials have assessed the efﬁcacy of
BMCtherapyinpatientstreatedwithprimaryPCI.Weperformed
cell transfer 7–12days before the ﬁrst PET and MRI studies, and
therefore can not exclude potential cell-mediated effects arising
beforehandandcausingourprotocoltounderestimatetherapeutic
effects of BMC therapy. There are no consensus or good meta-
analysis to reveal whether small or large infarct are more likely to
beneﬁt from stem cell therapy. Of the three largest clinical BMC
trials (Lunde et al., 2006; Meluzín et al., 2006; Schachinger et al.,
2006b), only REPAIR-AMI trial indicated that baseline EF cor-
related with EF change (p =0.04) but the statistical analysis did
not taken autocorrelation of the parameters into account, which
shouldbeconsideredasamajorlimitation.However,recentobser-
vations from small studies showed that large infarcts were less
likely to get beneﬁt from BMC therapy (Obradovi´ c et al., 2009;
Traverse et al., 2010). Global LV function was quite preserved
in our patient population, potentially improving the likelihood
of a positive outcome. We used LV angiography instead of MRI
for assessing cardiac function at baseline. A relatively small sam-
ple size together with a trend-type different EF and MI size at
baseline may also limit the generalization of the results. Another
potential confounding factor was the use of paclitaxel stents in all
patients, which may inﬂuence the function of the injected cells
itself. However, in the MAGIC Cell-3-DES study, drug-eluting
stents were used for all patients and the authors found improved
EF in BMC group vs. placebo (p =0.04; Kang et al., 2006), sug-
gesting that the stent is unlikely to explain the negative results in
our study.
CONCLUSION
Cardiac [15O]H2O-, [18F]FDG- and [11C]HED- PET, and MRI
offer attractive tools for measuring myocardium in detail after
BMC transfer. A trend of improvement in metabolism and
innervation defect may reﬂect slight recovery of jeopardized
myocardium in BMC-treated patients. However, BMC therapy in
infarct-related artery 3days after successfully reperfused STEMI
showed no consistently better outcome than placebo in this
patient group. Therefore, larger studies are needed before trying
to generalize the results from this pilot study.
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ONLINE RESOURCES
Online Resource 1: Short-axis cine MRI image (1week) in
BMC-treated patient. Short-axis cine MRI image stack at 1week
time-point from a patient with BMC therapy (same patient as
in Figure 4A). End-diastolic volume was 192mL and ejection
fraction 41%.
Online Resource 2: Short-axis cine MRI image (6months) in
BMC-treatedpatient.Short-axiscineMRIimagestackat6month
from the same patient with BMC therapy as in Online Resource 1.
End-diastolic volume was 204mL and ejection fraction 43%.
Online Resource 3: Short-axis cine MRI image (1week) in
placebotreatedpatient.Short-axiscineMRIimagestackat1week
from a patient with placebo therapy. Same patient as in Figure4B
end-diastolic volume was 182mL and ejection fraction 34%.
Online Resource 4: Short-axis cine MRI image (6months)
in placebo treated patient. Short axis cine MRI image stack
at 6month from the same patient with placebo therapy as in
OnlineResource3.End-diastolicvolumewas174mLandejection
fraction 36%.
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